It was the company’s first CAR T-cell therapy that was approved by the FDA in 2017 and is used for the treatment of large B-cell lymphoma in adult patients. PG13-CD19-H3 is the important starting material used to produce Yescarta. The new facility is dedicated to the manufacture of viral vectors such as replication-deficient gamma-retroviral vector PG13-CD19-H3 and replication-deficient lentiviral vector. The facility is staffed by a team of experts and operates under stringent regulatory guidelines to ensure that the finished products are safe, pure, and effective. The state-of-the-art viral vector manufacturing facility is a 100,000ft² building focused on the development and production of viral vectors in-house for pre-clinical or early-stage clinical trials, as well as commercial use. Kite Pharma’s viral vector manufacturing facility details In March 2022, Gilead purchased approximately 27 acres of land in Oceanside, next to the existing facility to support future manufacturing operations. Oceanside can be accessed through three highways, I-5, Highway 78, and Highway 76. Situated between Los Angeles and San Diego, Oceanside is connected to Los Angeles by Interstate I-405 South and to San Diego by Interstate I-5 North. The facility was purchased from Genentech in August 2011.

The viral vector manufacturing facility is located within Gilead’s existing biologics operation facility at 4049 Avenida de la Plata, Oceanside.

Location of the viral vector manufacturing facility

Kite pharma los angeles